Edge Therapeutics Inc. is a clinical-stage biotechnology company. The company is engaged in the development of hospital-based therapies designed to manage acute and life threatening neurological conditions. The company’s lead product candidate is designed to treat/manage aneurysmal subarachnoid hemorrhage (aSAH).